File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Target Therapy for Esophageal Adenocarcinoma

TitleTarget Therapy for Esophageal Adenocarcinoma
Authors
KeywordsEsophageal
Esophagogastric
Adenocarcinoma
Palliative
Target therapy
Immunotherapy
Issue Date2018
PublisherHumana Press.
Citation
Target Therapy for Esophageal Adenocarcinoma. In Lam, AK (Eds.), Esophageal Adenocarcinoma: Methods and Protocols, p. 51-65. New York, N.Y.: Humana Press, 2018 How to Cite?
AbstractAdenocarcinoma of the esophagus is a deadly disease and median survival of patients with metastatic disease is around 1 year only. There is an unmet need to personalize treatment by identifying molecular targets and respective target therapy in esophageal adenocarcinoma. There has been success in targeting the human epidermal growth factor receptor 2 (HER2) and vasoendothelial growth factor (VEGF) pathway while more failures were encountered in the clinical studies targeting epidermal growth factor (EGFR), mammalian target of rapamycin (mTOR), and mesenchymal-epithelial transition (MET). Studies using immune-checkpoint inhibitors have shown early success, and we await mature data for clinical application. In the chapter, the target therapy and novel treatment strategy will be reviewed. In the future, it is hoped that advances in translational research in targeted therapy against esophageal adenocarcinoma will bring about new progress in clinical practice.
Persistent Identifierhttp://hdl.handle.net/10722/263325
ISBN
ISSN
2023 SCImago Journal Rankings: 0.399
Series/Report no.Methods in Molecular Biology; v. 1756

 

DC FieldValueLanguage
dc.contributor.authorLam, KO-
dc.contributor.authorKwong, DLW-
dc.date.accessioned2018-10-22T07:37:03Z-
dc.date.available2018-10-22T07:37:03Z-
dc.date.issued2018-
dc.identifier.citationTarget Therapy for Esophageal Adenocarcinoma. In Lam, AK (Eds.), Esophageal Adenocarcinoma: Methods and Protocols, p. 51-65. New York, N.Y.: Humana Press, 2018-
dc.identifier.isbn9781493977338-
dc.identifier.issn1064-3745-
dc.identifier.urihttp://hdl.handle.net/10722/263325-
dc.description.abstractAdenocarcinoma of the esophagus is a deadly disease and median survival of patients with metastatic disease is around 1 year only. There is an unmet need to personalize treatment by identifying molecular targets and respective target therapy in esophageal adenocarcinoma. There has been success in targeting the human epidermal growth factor receptor 2 (HER2) and vasoendothelial growth factor (VEGF) pathway while more failures were encountered in the clinical studies targeting epidermal growth factor (EGFR), mammalian target of rapamycin (mTOR), and mesenchymal-epithelial transition (MET). Studies using immune-checkpoint inhibitors have shown early success, and we await mature data for clinical application. In the chapter, the target therapy and novel treatment strategy will be reviewed. In the future, it is hoped that advances in translational research in targeted therapy against esophageal adenocarcinoma will bring about new progress in clinical practice.-
dc.languageeng-
dc.publisherHumana Press.-
dc.relation.ispartofEsophageal Adenocarcinoma: Methods and Protocols-
dc.relation.ispartofseriesMethods in Molecular Biology; v. 1756-
dc.subjectEsophageal-
dc.subjectEsophagogastric-
dc.subjectAdenocarcinoma-
dc.subjectPalliative-
dc.subjectTarget therapy-
dc.subjectImmunotherapy-
dc.titleTarget Therapy for Esophageal Adenocarcinoma-
dc.typeBook_Chapter-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityKwong, DLW=rp00414-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/978-1-4939-7734-5_5-
dc.identifier.scopuseid_2-s2.0-85044825472-
dc.identifier.hkuros294875-
dc.identifier.spage51-
dc.identifier.epage65-
dc.identifier.eissn1940-6029-
dc.publisher.placeNew York, N.Y.-
dc.identifier.issnl1064-3745-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats